Incidence Rates for Major Cancer Sites by Gender | Zanran
Data & statistics on Incidence Rates for Major Cancer Sites by Gender: Estimated Age-Standardized Incidence Rates for Major Cancer Sites by Gender and Province, Canada, 2002, Incidence Rates for Major Cancer Sites by Gender, Estimated Age-Standardized Incidence Rates for Major Cancer Sites by Sex and Province, Canada, 2006...http://www.zanran.com/q/Incidence_Rates_for_Major_Cancer_Sites_by_Gender
Molecular Cancer | Home page
|p||table||tr||td||p||i|Molecular Cancer |/i|is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.|br/||br/||i|Molecular Cancer |/i|provides an important forum for exciting findings in cancer-related research, presenting an unparalleled opportunity to communicate information to specialists and the public. |/p||p||i|Molecular Cancer|/i| is interested in articles from basic, translational and clinical research. Topics of interest include, but are not limited to: tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signaling and molecular biology, epidemiology, genetic and molecular profiling of cancer targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, virology and vaccine- and antibody-based cancer therapies.|/p||/td||/tr||/table||/p|http://www.molecular-cancer.com
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members -...
The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is being screened at the NIH for eligibility for an NIH Clinical Center treatment protocol.. OR. The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is already enrolled on a clinical protocol at the NIH Clinical Center.. OR. The subject is a related HLA-compatible family member of a patient (bearing a diagnosis of malignant solid tumor or a malignant or non-malignant hematologic) being evaluated for or already enrolled on a clinical protocol at the NIH Clinical Center and is identified as a potentially suitable donor of allogeneic hematopoietic stem cells for transplantation.. OR. The subject carries the diagnosis of malignant solid tumor or a malignant or non malignant hematologic disorder or a bone marrow failure condition and is not available to participate in an NIH Clinical Center treatment protocol, or travel ...https://clinicaltrials.gov/ct2/show/NCT00071045
Zaman Receives $3M Grant to Model How Cancer Spreads: NIH Funds Five-Year Project with Focus on Breast Cancer
Despite deep cuts in federal research spending due to sequestration, Associate Professor Muhammad Zaman (BME, MSE) has secured a five-year grant of more than $3 million from the National Institutes of Health to develop mathematical and computational models of how breast cancer cells move and communicate as they migrate from tumors, invade nearby tissue and proliferate.. By mapping this process from the molecular to the cellular level through detailed, comprehensive multiscale models based on strong experimental and computational data, Zaman and his collaborators-MIT Professors Frank Gertler, Roger Kamm and Douglas Lauffenberger, and a computational modeling team in Singapore-aim to uncover new pathways to control tumor development and metastasis in the breast, lung, and other organs.. Complex biochemical and biomechanical interactions govern how cancer cells spread from tumors and metastasize in nearby tissue. Much is known about the mechanics of how cancer cells migrate, but how biochemical ...http://www.bu.edu/eng/2013/05/20/zaman-receives-3m-grant-to-model-how-cancer-spreads-nih-funds-five-year-project-with-focus-on-breast-cancer/
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors | Clinical Cancer Research
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.. Experimental Design: In this phase I, open-label, dose-escalation study, patients received 35 to 160 mg of dasatinib twice daily in 28-day cycles either every 12 hours for 5 consecutive days followed by 2 nontreatment days every week (5D2) or as continuous, twice-daily (CDD) dosing.. Results: Sixty-seven patients were treated (5D2, n = 33; CDD, n = 34). The maximum tolerated doses were 120 mg twice daily 5D2 and 70 mg twice daily CDD. DLTs with 160 mg 5D2 were recurrent grade 2 rash, grade 3 lethargy, and one patient with both grade 3 prolonged bleeding time and grade 3 hypocalcemia; DLTs with 120 mg twice daily CDD were grade 3 nausea, grade 3 fatigue, and one patient with both grade 3 rash and grade 2 proteinuria. The most frequent treatment-related toxicities ...http://clincancerres.aacrjournals.org/content/15/19/6232.short
Evaluation of state comprehensive cancer control plans for genomics content.
Comprehensive Cancer Control (CCC) plans address cancer burden at the state level through consolidation of activities and collaboration among stakeholders. Public health genomics strategies are increasingly important in prevention and treatment of cahttp://www.biomedsearch.com/nih/Evaluation-state-comprehensive-cancer-control/23256909.html
Immunotherapy for elderly cancer patients finds new promise in drug combination
We've shown that an aged immune system can combat cancer just as well as a young one if you remove the impediments to successful immunity, which are different that those in younger hosts," Dr. Curiel said. "We've shown that if you test all your immune therapy just in young mice and young people, you'll never learn how it works in older patients - the ones most at risk for cancer. You might conclude that drugs don't work in aged hosts, when they do. But they have to be combined with some help.". After discovering this in melanoma, the researchers then looked at whether the same action held true in colon cancer, a major cancer killer in the elderly.. "The details were different in colon cancer. The bad immune cells that increased in the aged mice and how they were knocked down by the drugs were different than in melanoma," Dr. Curiel said. "But the result was the same - we identified a drug combination that was highly effective in the aged mice.". That means that not only must this strategy be ...http://www.innovations-report.com/html/reports/medicine-health/immunotherapy-elderly-cancer-patients-finds-promise-193926.html
Molecular Evolutionary Analysis of Cancer Cell Lines | Molecular Cancer Therapeutics
Thank you for sharing this Molecular Cancer Therapeutics article.. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.. ...http://mct.aacrjournals.org/content/9/2/279.article-info
Inorganic phosphate and the risk of cancer in the Swedish AMORIS study
Background: Both dietary and serum levels of inorganic phosphate (Pi) have been linked to development of cancer in experimental studies. This is the first population-based study investigating the relation between serum Pi and risk of cancer in humans. Methods: From the Swedish Apolipoprotein Mortality Risk (AMORIS) study, we selected all participants (,20 years old) with baseline measurements of serum Pi, calcium, alkaline phosphatase, glucose, and creatinine (n = 397,292). Multivariable Cox proportional hazards regression analyses were used to assess serum Pi in relation to overall cancer risk. Similar analyses were performed for specific cancer sites. Results: We found a higher overall cancer risk with increasing Pi levels in men (HR: 1.02 (95% CI: 1.00-1.04) for every SD increase in Pi), and a negative association in women (HR: 0.97 (95% CI: 0.96-0.99) for every SD increase in Pi). Further analyses for specific cancer sites showed a positive link between Pi quartiles and the risk of cancer of ...http://www.diva-portal.org/smash/record.jsf?pid=diva2:636187
Gentaur Molecular :Biochai \ cDNA Panel Human Tumor Tissue, Different Tumor Type, Different Donors \ C8235547
Gentaur molecular products has all kinds of products like :Biochai , Biochai \ cDNA Panel _ Human Tumor Tissue, Different Tumor Type, Different Donors \ C8235547 for more molecular products just contact ushttp://www.antibody-antibodies.com/product174403-Biochai-cDNA_Panel___Human_Tumor_Tissue,_Different_Tumor_Type,_Different_Donors.html
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors - Full Text View - ClinicalTrials.gov
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists (surgery, radiotherapy, and/or chemotherapy) Measurable or evaluable disease by medical photograph, plain x-ray, CT, MRI, palpation, or serum tumor markers at least 2 times upper limit of normal No symptomatic, progressive brain metastases by CT or MRI scan No cerebral edema No leukemia or multiple myeloma. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL No coagulation disorders Hepatic: Bilirubin normal AST and ALT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN if liver involvement) PT or INR, and PTT normal Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No cardiac conduction abnormalities ...https://clinicaltrials.gov/ct2/show/NCT00004049
bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in...
Health,...SAN DIEGO Oct. 6 /- bioTheranostics a bioMerieux compan...Under the terms of the agreement UK-based Lab21 will market the THERO...The CTID assay is a 92-gene molecular cancer classifier that identifie... We recognize a tremendous need globally for new technologies that wil...,bioTheranostics,Announces,Commercial,Agreement,With,Lab21,to,Market,THEROS,CancerTYPE,ID(R),Molecular,Cancer,Classifier,in,United,Kingdom,,Ireland,and,Middle,East,Countries,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine newshttp://www.bio-medicine.org/medicine-news-1/bioTheranostics-Announces-Commercial-Agreement-With-Lab21-to-Market-THEROS-CancerTYPE-ID-28R-29-Molecular-Cancer-Classifier-in-United-Kingdom--Ireland-58927-1/
Phase I trial of R115777 [tipifarnib] (NSA 702818) in advanced malignant solid tumours - AdisInsight
Restricted Access Oops, it looks like you don't have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...http://adisinsight.springer.com/trials/700002720?error=cookies_not_supported&code=81e89b36-4cf6-4893-ba96-9793f32ff864
2015-2019 Future Horizons and Growth Strategies in the Global Cancer Diagnostics Market: Supplier Shares and Country Forecasts
... 2015-2019 Future Horizons and Growth Strategies in the - Market research report and industry analysis - 9280046https://www.marketresearch.com/Venture-Planning-Group-v3447/Future-Horizons-Growth-Strategies-Global-9280046/
'Chase-and-run' cells offer new clues on how cancer spreads | CTV News
A team of British scientists has shed more light on how cancer might be spread in the body, describing a so-called 'chase-and-run' phenomenon involving malignant and healthy cells.http://www.ctvnews.ca/health/chase-and-run-cells-offer-new-clues-on-how-cancer-spreads-1.1328911
Errant neuro-developmental gene implicated in brain cancer
Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meeting attracts more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research. ...http://www.rxpgnews.com/cancer/brain/article_306.shtml
Psycho-Oncology - Jimmie C. Holland, William S. Breitbart, Paul B. Jacobsen, Matthew J. Loscalzo, Ruth McCorkle, Phyllis N....
Originally published by Oxford in 1998, Psycho-Oncology was the first comprehensive text in the field and remains the gold standard today. Edited by a team of leading experts in psycho-oncology, spearheaded by Dr. Jimmie C. Holland, the founder of the field, the text reflects the interdisciplinary nature and global reach of this growing field.https://global.oup.com/academic/product/psycho-oncology-9780199363315?cc=es&lang=en&
Cancer Prevention after Cancer: Changing the Paradigm-a Report from the American Society of Preventive Oncology | Cancer...
Research indicates that physical activity not only helps prevent cancer (29, 30), it also confers mortality benefits for cancer survivors (31, 32). Yet, current cancer therapies do not address the association of lifestyle factors on prognosis and survivorship, despite the fact that obesity, weight gain, and physical inactivity are common in cancer patients before and after a cancer diagnosis (33). There is a strong association between having a higher body mass index (BMI) before cancer diagnosis and mortality from different cancer types. For instance, uterine cancer survivors who had a prediagnosis BMI greater than 35 have a 6-fold increase risk of mortality compared with survivors who had a prediagnosis BMI less than 25 (34). In early-stage breast cancer, a BMI greater than or equal to 40 is associated with at least a 5-fold increase of mortality risk compared with BMI less than 25 (35). Furthermore, a higher BMI may explain up to 14% and 20% of all deaths from cancer in men and women, ...http://cebp.aacrjournals.org/content/20/10/2317.long
BN80927 in Patients With Advanced Malignant Solid Tumors - Full Text View - ClinicalTrials.gov
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies. ...https://clinicaltrials.gov/ct2/show/NCT01435096
Cancer is a major health problem that can debilitate and destroy human lives. One out of every 4 deaths in the United States is caused by cancer. More than $124.6 billion was spent in direct medical costs for 13.7 million cancer survivors and 1.5 million newly diagnosed cancer patients in the United States in 2010. Increasing human life expectancy will inevitably raise cancer prevalence and the related costs. Consequently, the development of effective cancer prevention strategies is increasingly important. Histologically, the development of cancer involves multiple steps, which occur over several years after the initial carcinogen exposure from normal to hyperplasia, mild, moderate, and severe dysplasia, and carcinoma in situ, before finally progressing to invasive cancer (1). Throughout this long, multi-step developmental course, there is a wide scope of possible preventive approaches that can delay or prevent the development of cancer. Different cancer prevention strategies such as behavioral ...http://cancerpreventionresearch.aacrjournals.org/content/6/5/387
Genetic makeup may make radiation riskier for pediatric cancer patients
Genetic vulnerabilities associated with childhood cancers may make children undergoing radiation therapy more susceptible than adults to secondary cancers, according to novel insights from researchers at UC San Francisco.https://medicalxpress.com/print360568247.html
Removing cancer cell debris improves conventional cancer treatments | EurekAlert! Science News
Cancer therapies are designed to kill tumor cells, but produce tumor cell debris in the process. In a study published in The Journal of Experimental Medicine, researchers from Brigham and Women's Hospital and colleagues show that leftover debris can stimulate inflammation and tumor growth, but that molecules called resolvins can block that unwanted inflammatory response. The findings point towards a new way to enhance the effectiveness of current cancer therapies and potentially prevent tumor recurrence.https://eurekalert.org/pub_releases/2017-12/bawh-rcc120417.php
Human myeloid derived suppressor cells (MDSC) have been described as CD14-CD11b+CD33+HLADR- cells that exert T cell suppression via ROS, ARG1 and iNOS2. Here, we report a novel myeloid subset found within mononuclear fraction elutriated from apheresis samples of pediatric cancer patients vs. healthy controls. Of 60 pediatric cancer patients studied, we frequently observed expanded numbers of CD14-CD123-CD11chi cells, which were rare and found only at low levels in healthy donors. Like previously described MDSC, these cells were CD11b+, but CD33lo/-HLADR+. In addition, these abnormal myeloid cells were CD34+CD15+CD16+CD66b+CD68+PDL1+ and IL4Rα+. Interestingly they also expressed α smooth muscle actin and collagen I/V on their surface, which are hallmarks of fibrocytes. The fibrocytes expressed high levels of indoleamine oxidase (IDO), but did not express ARG1, ARG2, iNOS2. They suppressed T cell proliferation in response to OKT3, which was partially reversed by the addition of 1MT, an inhibitor ...http://cancerres.aacrjournals.org/content/72/8_Supplement/LB-127
A Systematic Review of Interventions with Siblings of Pediatric Cancer Patients
형제자매는 일생 동안 서로 지속적인 유대 속에서 부모의 관심과 사랑을 공유하는 관계이다. 그런데 한 아동이 암 진단을 받게 되는 경우 치료를 받는 과정부터 치료 이후의 회복기간 중에도 질병과 건강의 불확실성에 대처하며 일상의 변화에 적응해야 하기 때문에 가족 모두의 관심은 소아암 환자에게 집중되기 쉬우며, 이 과정에서 소아암 환자의 형제자매들도 어려움을 경험하게 된다. 즉, 소아암 환자의 형제자매들은 개인적인 또는 가족 및 대인관계의 측면에서 다양한 신체적 · 심리사회적 ·영적 영향을 받게 되는데, 개인적 측면에서는 슬픔, 외로움, 거부당한 느낌, 분노, 질투, 불안에 이르기까지 다양한 감정의 변화를 경험하게 되며 때로는 신체화 증상이나 우울증으로 나타나기도 한다. 또한 소아암 환자의 형제자매들은 가족 내에서는 부모와 ...http://www.e-chnr.org/journal/view.php?number=1557
Journal Highlight: How many proteins can be identified in a 2-DE gel spot within an analysis of a complex human cancer tissue...
How many proteins can be identified in a 2-DE gel spot within an analysis of a complex human cancer tissue proteome Electrophoresis , 2018, online Xianquan Zhan, Haiyan Yang, Fang Peng, Jianglin Li, Yun Mu, Ying Long, Tingting Cheng, Yuda Huang, Zhao Li, Miaolong Lu, Na Li, Maoyu Li, Jianping Liu and Peter R. Jungblut Abstract Two-dimensional gel...http://www.separationsnow.com/proteomic/details/ezine/160a85fcc02/Journal-Highlight-How-many-proteins-can-be-identified-in-a-2-DE-gel-spot-within-.html